Posted by Michael Wonder on 27 Jan 2022
FDA grants breakthrough therapy designation for Dizal Pharmaceutical's DZD9008 in patients with locally advanced or metastatic non-small cell lung cancer harbouring EGFR Exon 20 insertion
27 January 2022 - Breakthrough therapy designation further demonstrates excellent clinical profile of DZD9008 (sunvozertinib).
Dizal Pharmaceutical today announced that the U.S. FDA has granted breakthrough therapy designation to DZD9008 (sunvozertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
